Dishman Carbogen Amcis Ltd has approved the issuance of non-convertible debentures (NCDs) worth up to ₹1 billion on a private placement basis. The move is aimed at strengthening the company’s capital structure and supporting future growth initiatives, subject to necessary regulatory approvals.
The pharmaceutical company, known for its contract development and manufacturing services, confirmed the board’s approval during its recent meeting. The issuance of NCDs will provide long-term funding flexibility and help meet operational and expansion requirements.
Fundraising Details
The NCDs will be issued on a private placement basis, targeting institutional investors. This fundraising initiative is expected to improve liquidity and reduce reliance on short-term borrowings. The company has emphasized that the proceeds will be utilized for business expansion, debt refinancing, and working capital needs.
Strategic Importance
By opting for NCDs, Dishman Carbogen Amcis aims to diversify its funding sources while maintaining financial discipline. The move reflects a broader trend among pharmaceutical companies to secure stable financing amid rising competition and global demand for contract manufacturing services.
Future Outlook
Analysts believe the issuance will strengthen the company’s balance sheet and support its long-term growth strategy. With increasing opportunities in global pharmaceutical outsourcing, the capital infusion is expected to enhance operational capabilities and market competitiveness.
Key Highlights
-
Dishman Carbogen Amcis approves issue of up to ₹1 billion NCDs
-
Issuance to be done on private placement basis
-
Funds to be used for expansion, debt refinancing, and working capital
-
Move strengthens capital structure and financial flexibility
Sources: InvestyWise, MarketScreener, AxisDirect